$INNV | An Undervalued Pharma Company with Strong Commercial Pipeline and Solid Revenues
https://www.youtube.com/watch?v=f7YnqjVLVg0
In the interview, Dr. Damaj highlighted short-term goals for Innovus Pharma, which includes:
1. The new acquired Beyond Human product which generated over $2.2M in 2015;
2. The projected move to being cash flow positive exiting 2016 and profitable exiting 2017 and;
3. The plans for future uplisting the company onto the NYSE exchange in 2016.
Dr. Damaj, who took the reins of Innovus as CEO in late January 2013, noted that the 10 commercial partnerships signed for the Company’s products with over $500M in potential sales milestones, the commercialization of its products in multiple countries and the acquisition of Beyond Human’s $2.2M generating products have been instrumental in growing the Company’s revenues and setting it up for potentially exiting 2016 in a cash flow positive mode and move to profitability in 2017.
“Innovus has a deep and strong product commercial pipeline that generated consistent revenues for the Company with a focus on men’s health, women’s health, vitality and respiratory diseases”, Dr. Damaj said. “The Company’s products are becoming lead product in the markets they are launched in which is a testimony to the clinical efficacy of the product over current competition,” he continued.
With regard to funding, Damaj noted that the Company was successful in raising close to $2.5M from institutional investors in the last 6 months, which has provided it with better financial security.
